Antibody-Based and Ligand-Based Drugs for Targeted Cancer Therapy
(0) The research and development of antibody-based drugs, monoclonal antibody therapeutics, have shown great momentum in the field of biotech medicines. Because of the high specificity to related molecular target, a panel of antibody-based drugs has been successfully used in clinical cancer therapy 1-3. Recently, ligand-based drugs have attracted much attention in the manufacture of targeted drugs owing to the highly specific binding of the ligand to its receptor. In addition, the antibody-based or ligand-based molecules can serve as a carrier for targeted drug delivery. Based on the highly specific interaction of antibody-antigen or ligand-receptor, the constituted drugs display their selectivity to related cancer cells and tumor-homing properties. For antibody therapeutics, the immunoglobulin itself can be effective. However, to further improve the efficacy of antibody-based drug for cancer, increasing its potency of cytotoxicity to target cancer cells is needed. This can be realized by integration of a highly potent “warhead effector agent into the antibody molecule to form chemical conjugate or genetically engineered fusion protein. Accordingly, ligand-based drug can be prepared by linking a ligand peptide motif (LPF) to an effector molecule to form corresponding conjugate or fusion protein. Moreover, both of an antibody fragment and a LPT can be integrated into the molecule of conjugate or fusion protein, resulting in a drug with bi-specific activity.
Zhen Yongsu
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
国际会议
International Symposium on Crystal Engineering and Drug Delivery System 2009(2009晶体工程与药物传送系统国际会议)
天津
英文
313-314
2009-09-05（万方平台首次上网日期，不代表论文的发表时间）